LETTER
Adverse Effects of ACE Inhibitors
James W. Adams and
Patrick B. Hazard
15 February 1993 | Volume 118 Issue 4 | Pages 314-315
TO THE EDITOR:
We read with interest the article by Israeli and Hall [1]. No mention was made of the use of cromolyn inhalation therapy for persistent cough due to ACE inhibitor therapy [2]. Withdrawal of the ACE inhibitor is an appropriate first step, but care must be exercised to avoid exacerbations of hypertension, heart failure, or other disease processes. Although no double-blind, placebo-controlled study of the use of cromolyn in ACE-inhibitor-induced chronic cough has been done, such measures should be considered when faced with this increasingly common problem.
1. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992; 117:234-42.
2. Aldis WL. Cromolyn for cough due to angiotensin-converting enzyme inhibitor therapy. Chest. 1991; 100:6.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
References
Article
